In particular, by blocking programmed cell death (PD-1)/programmed death ligand (PD-L1) interaction or other checkpoints, e.g., cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), ICI restore immune surveillance against malignant cells and improve clinical responses and survival in many tumor types [2,3]. This evidence concerns the gene CD274 and neoplasm.